oral antiviral drug

LONDON, UK: Beximco Pharmaceuticals Limited announced the launch of the world’s first generic molnupiravir, an oral antiviral drug for symptomatic COVID-19 recently developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics. The announcement comes following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh. Beximco Pharma’s branded…